,3,4,6-Tetra-O-benzyl-D-gluconic acid-δ-lactone | CAS:13096-62-3

We serve ,3,4,6-Tetra-O-benzyl-D-gluconic acid-δ-lactone CAS:13096-62-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
,3,4,6-Tetra-O-benzyl-D-gluconic acid-δ-lactone

Chemical Name:2,3,4,6-Tetra-O-benzyl-D-gluconic acid-δ-lactone
CAS.NO:13096-62-3
Synonyms:2,3,4,6-Tetra-O-benzyl-D-glucono-1,5-lactone(3R,4S,5R,6R)-3,4,5-tris(phenylmethoxy)-6-(phenylmethoxymethyl)oxan-2-one
2,3,4,6-Tetra-O-benzyl-D-glucono-1,5-lactone
(3R,4S,5R,6R)-3,4,5-tris(phenylmethoxy)-6-(phenylmethoxymethyl)oxan-2-one
(3R,4S,5R,6R)-3,4,5-Tris(benzyloxy)-6-[(benzyloxy)methyl]tetrahydro-2H-pyran-2-one
2,3,4,6-Tetrakis-O-(phenylmethyl)-D-gluconic acid lactone

Molecular Formula:C34H34O6

Molecular Weight:538.63000
 
Specification:
Appearance:Light yellow liquid or crystal
Purity:≥95.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Ipragliflozin、Empagliflozin、Dapagliflozin、Tofogliflozin
 
Note:The product under valid patents will not be offered to the countries covered by patents.



Contact us for information like 2,3,4,6-Tetra-O-benzyl-D-glucono-1,5-lactone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,3,4,6-Tetrakis-O-(phenylmethyl)-D-gluconic acid lactone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,3,4,6-Tetra-O-benzyl-D-glucono-1,5-lactone Use and application,2,3,4,6-Tetra-O-benzyl-D-glucono-1,5-lactone technical grade,usp/ep/jp grade.


Related News: Since inception in 2004, ICIG has acquired 15 businesses, all of which have origins in major global chemical or pharmaceutical corporations and are independently managed.3,4-Difluorobenzyl Bromide manufacturer Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.2-Amino-9,9-dimethylfluorene supplier Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.2-Bromo-4-trifluoromethoxyaniline vendor Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.